These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 6504328)

  • 1. Suppression of L-dopa-induced circling in rats with nigral lesions by blockade of central dopa-decarboxylase: implications for mechanism of action of L-dopa in parkinsonism.
    Melamed E; Hefti F; Bitton V; Globus M
    Neurology; 1984 Dec; 34(12):1566-70. PubMed ID: 6504328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The central aromatic amino acid DOPA decarboxylase inhibitor, NSD-1015, does not inhibit L-DOPA-induced circling in unilateral 6-OHDA-lesioned-rats.
    Treseder SA; Rose S; Jenner P
    Eur J Neurosci; 2001 Jan; 13(1):162-70. PubMed ID: 11135014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic effects of L-dopa are not closely linked temporally to striatal dopamine concentration.
    Spencer SE; Wooten GF
    Neurology; 1984 Dec; 34(12):1609-11. PubMed ID: 6504335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous microdialysis in striatum and substantia nigra suggests that the nigra is a major site of action of L-dihydroxyphenylalanine in the "hemiparkinsonian" rat.
    Orosz D; Bennett JP
    Exp Neurol; 1992 Mar; 115(3):388-93. PubMed ID: 1537396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of Chronic Treatment with the Inhibitor of Phosphodiesterase 5 (PDE5), Sildenafil, in Combination with L-DOPA on Asymmetric Behavior and Monoamine Catabolism in the Striatum and Substantia Nigra of Unilaterally 6-OHDA-Lesioned Rats.
    Lorenc-Koci E; Kamińska K; Lenda T; Konieczny J
    Molecules; 2024 Sep; 29(18):. PubMed ID: 39339313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The site of dopamine formation in rat striatum after L-dopa administration.
    Hefti F; Melamed E; Wurtman RJ
    J Pharmacol Exp Ther; 1981 Apr; 217(1):189-97. PubMed ID: 7205652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Muscarinic antagonists in substantia nigra influence the decarboxylation of L-dopa in striatum.
    Izurieta-Sánchez P; Sarre S; Ebinger G; Michotte Y
    Eur J Pharmacol; 2000 Jul; 399(2-3):151-60. PubMed ID: 10884514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine release in rat striatum after administration of L-dope as studied with in vivo electrochemistry.
    Hefti F; Melamed E
    Brain Res; 1981 Nov; 225(2):333-46. PubMed ID: 7306794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence that the substantia nigra is a site of action for L-DOPA.
    Robertson GS; Robertson HA
    Neurosci Lett; 1988 Jun; 89(2):204-8. PubMed ID: 3393296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats.
    Yamada H; Aimi Y; Nagatsu I; Taki K; Kudo M; Arai R
    Neurosci Res; 2007 Sep; 59(1):1-7. PubMed ID: 17586078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopaminergic functional supersensitivity: effects of chronic L-dopa and carbidopa treatment in an animal model of Parkinson's disease.
    Hossain MA; Weiner N
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1105-11. PubMed ID: 8263772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotonergic activation after 2-week intrastriatal infusion of L-dopa and slow recovery of circling in rats with unilateral nigral lesions.
    Kääriäinen TM; García-Horsman JA; Piltonen M; Huotari M; Männistö PT
    Basic Clin Pharmacol Toxicol; 2008 Mar; 102(3):300-7. PubMed ID: 17973898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence that L-dopa-induced rotational behavior is dependent on both striatal and nigral mechanisms.
    Robertson GS; Robertson HA
    J Neurosci; 1989 Sep; 9(9):3326-31. PubMed ID: 2795165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intracerebral dialysis monitoring of striatal dopamine release and metabolism in response to L-dopa.
    Brannan T; Knott P; Kaufmann H; Leung L; Yahr M
    J Neural Transm; 1989; 75(2):149-57. PubMed ID: 2918307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decarboxylation of exogenous L-DOPA in rat striatum after lesions of the dopaminergic nigrostriatal neurons: the role of striatal capillaries.
    Melamed E; Hefti F; Wurtman RJ
    Brain Res; 1980 Sep; 198(1):244-8. PubMed ID: 7407592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circling behavior following unilateral kainic acid injections into rat striatum.
    Taylor RJ; Reavill C; Jenner P; Marsden CD
    Eur J Pharmacol; 1981 Dec; 76(2-3):211-22. PubMed ID: 7333356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Striatal L-dopa metabolism studied in vivo in rats with nigrostriatal lesions.
    Brannan T; Bhardwaj A; Martinez-Tica J; Weinberger J; Yahr M
    J Neural Transm Park Dis Dement Sect; 1990; 2(1):15-22. PubMed ID: 2113388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum.
    Biggs CS; Starr MS
    Synapse; 1999 Oct; 34(1):36-46. PubMed ID: 10459170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
    Lindgren HS; Andersson DR; Lagerkvist S; Nissbrandt H; Cenci MA
    J Neurochem; 2010 Mar; 112(6):1465-76. PubMed ID: 20050978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered pharmacokinetics of L-dopa metabolism in rat striatum deprived of dopaminergic innervation.
    Spencer SE; Wooten GF
    Neurology; 1984 Aug; 34(8):1105-8. PubMed ID: 6540390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.